방사성 요오드 치료 후 발생하는 타액선염 = Radioactive Iodine-Induced Sialadenitis

다국어 초록 (Multilingual Abstract)

Radioactive iodine (131I) targets the thyroid gland and has been proven to play an effective role in the treatment of differentiated thyroid cancers. However, this radioisotope is simultaneously absorbed on the salivary glands where it is concentrated and secreted into the saliva. Dose related damage to the salivary parenchyma results from the 131I irradiation. Salivary gland swelling and pain, usually involving the parotid, can be seen. The symptoms may develop immediately after a therapeutic dose of 131I and/or months later and progress in intensity with time. Prevention of the 131I-induced sialadenitis includes the use of sialagogic agents to enhance the transit time of the 131I through the salivary glands. However, many studies are not available to delineate the efficacy of this approach. Recently, amifostine has been advocated to prevent the effects of irradiation. Treatment of the varied complications that may develop encompass numerous approaches and include gland massage, sialagogic agents, duct probing, antibiotics, mouthwashes, good oral hygiene, and adequate hydration.

참고문헌 (Reference)

1 Jentzen W, "The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging" 37 (37): 2298-2306, 2010

2 Schneyer LH, "Source of resting total mixed saliva of man" 9 (9): 79-81, 1956

3 Van Nostrand D, "Side effects of “rational dose”iodine-131 therapy for metastatic well-differentiated thyroid carcinoma" 27 (27): 1519-1527, 1986

4 Nahlieli O, "Sialadenitis following radioiodine therapy - a new diagnostic and treatment modality" 12 (12): 476-479, 2006

5 Allweiss P, "Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication" 25 (25): 755-758, 1984

6 Becciolini A, "Serum amylase and tissue polypeptide antigen as biochemical indicators of salivary gland injury during iodine-131 therapy" 21 (21): 1121-1125, 1994

7 Caglar M, "Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment" 27 (27): 767-771, 2002

8 Hyer S, "Salivary gland toxicity after radioiodine therapy for thyroid cancer" 19 (19): 83-86, 2007

9 Semin Nucl Med, "Salivary gland scinti-scanning with technetium 99m pertechnetate" 79 (79): 1105-1117, 1969

10 Bohuslavizki KH, "Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study" 16 (16): 3542-3549, 1998

11 Young-Mo Kim, "Salivary gland function after sialendoscopy for treatment of chronic radioiodine-induced sialadenitis" Wiley-Blackwell 38 (38): 51-58, 2014

12 Jeong SY, "Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms" 23 (23): 609-616, 2013

13 Wiesenfeld D, "Salivary gland dysfunction following radioactive iodine therapy" 55 (55): 138-141, 1983

14 Solans R, "Salivary and lacrimal gland dysfunction (sicca syndrome)after radioiodine therapy" 42 (42): 738-743, 2001

15 Jentzen W, "Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer" 27 (27): 669-676, 2006

16 Silberstein EB, "Reducing the incidence of 131I-induced sialadenitis:the role of pilocarpine" 49 (49): 546-549, 2008

17 Van Nostrand D, "Radiopharmacokinetics of radioiodine in the parotid glands after the administration of lemon juice" 20 (20): 1113-1119, 2010

18 Mishkin FS, "Radionuclide salivary gland imaging" 11 (11): 258-265, 1981

19 Mandel SJ, "Radioactive iodine and the salivary glands" 13 (13): 265-271, 2003

20 Bohuslavizki KH, "Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine" 17 (17): 681-686, 1996

21 Malpani BL, "Quantification of salivary gland function in thyroid cancer patients treated with radioiodine" 35 (35): 535-540, 1996

22 Aframian DJ, "Pilocarpine for the treatment of salivary glands’ impairment caused by radioiodine therapy for thyroid cancer" 12 (12): 297-300, 2006

23 Shiboski CH, "Management of salivary hypofunction during and after radiotherapy" 103 (103): S66.e1-S66.e19, 2007

24 Kim SJ, "Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan" 18 (18): 325-331, 2008

25 Alexander C, "Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma" 39 (39): 1551-1554, 1998

26 Liu B, "Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial" 51 (51): 618-623, 2010

27 Maier H, "Effect of radioactive iodine therapy on parotid gland function" 103 (103): 318-324, 1987

28 Nakada K, "Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?" 46 (46): 261-266, 2005

29 Ma C, "Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer" 37 (37): 1778-1785, 2010

30 Haddad P, "A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia" 64 (64): 29-32, 2002